Contrasting Immunovant (NASDAQ:IMVT) and Clarus Therapeutics (NASDAQ:CRXT)

Immunovant (NASDAQ:IMVTGet Rating) and Clarus Therapeutics (NASDAQ:CRXTGet Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, earnings, profitability, analyst recommendations, valuation and risk.

Institutional and Insider Ownership

34.5% of Immunovant shares are owned by institutional investors. Comparatively, 9.3% of Clarus Therapeutics shares are owned by institutional investors. 3.0% of Immunovant shares are owned by company insiders. Comparatively, 5.3% of Clarus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Immunovant and Clarus Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant 0 1 3 0 2.75
Clarus Therapeutics 0 2 0 0 2.00

Immunovant presently has a consensus price target of $10.67, indicating a potential upside of 107.93%. Clarus Therapeutics has a consensus price target of $2.50, indicating a potential upside of 7,592.31%. Given Clarus Therapeutics’ higher probable upside, analysts clearly believe Clarus Therapeutics is more favorable than Immunovant.

Volatility & Risk

Immunovant has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Clarus Therapeutics has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.

Earnings and Valuation

This table compares Immunovant and Clarus Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immunovant N/A N/A -$156.73 million ($1.47) -3.49
Clarus Therapeutics $13.96 million 0.12 -$40.62 million ($1.30) -0.03

Clarus Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Clarus Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Immunovant and Clarus Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immunovant N/A -34.22% -31.98%
Clarus Therapeutics -193.00% N/A -87.75%

Summary

Clarus Therapeutics beats Immunovant on 8 of the 13 factors compared between the two stocks.

About Immunovant

(Get Rating)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

About Clarus Therapeutics

(Get Rating)

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.